Fig. 2: High somatic alterations in patients sensitive to combination therapy. | Cancer Gene Therapy

Fig. 2: High somatic alterations in patients sensitive to combination therapy.

From: The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient

Fig. 2

A Baseline WES results of one responder (R) and three non-responders (NR1, NR2, NR3), showing the mutation frequencies across different genes. B, C The proportion of different gene mutation types in the responder patient and non-responded patient. D Missense mutation number in responded and non-responded patients. E Number of Snvs with allelic frequency greater than 10% in four enrolled patients. F–H Baseline metrics including MSI score, TMB and maximum allelic frequency in the four patients. I–L Higher gene expression in the responder patient for pathways related to virus replication and cell entry, tumor metabolism, degradation of extracellular matrix, and impaired pre-existing immunity. M KEGG pathway analysis of baseline RNA-seq data. N GO analysis of baseline RNA-seq data, providing insights into the biological processes, molecular functions, and cellular components involved.

Back to article page